Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma

Carolyn D. Runowicz, Scott Wadler, Lorna Rodriguez-Rodriguez, Peter Litwin, Mark Shaves, Katherine A. O'Hanlan, Gary L. Goldberg, Catherine T. Tomainov, Richard Byrnes

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalGynecologic Oncology
Volume34
Issue number3
DOIs
StatePublished - 1989

Fingerprint

Cisplatin
Radiotherapy
Uterine Cervical Neoplasms
Carcinoma
Tumor Burden
Squamous Cell Carcinoma
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Runowicz, C. D., Wadler, S., Rodriguez-Rodriguez, L., Litwin, P., Shaves, M., O'Hanlan, K. A., ... Byrnes, R. (1989). Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecologic Oncology, 34(3), 395-401. https://doi.org/10.1016/0090-8258(89)90180-7

Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. / Runowicz, Carolyn D.; Wadler, Scott; Rodriguez-Rodriguez, Lorna; Litwin, Peter; Shaves, Mark; O'Hanlan, Katherine A.; Goldberg, Gary L.; Tomainov, Catherine T.; Byrnes, Richard.

In: Gynecologic Oncology, Vol. 34, No. 3, 1989, p. 395-401.

Research output: Contribution to journalArticle

Runowicz, CD, Wadler, S, Rodriguez-Rodriguez, L, Litwin, P, Shaves, M, O'Hanlan, KA, Goldberg, GL, Tomainov, CT & Byrnes, R 1989, 'Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma', Gynecologic Oncology, vol. 34, no. 3, pp. 395-401. https://doi.org/10.1016/0090-8258(89)90180-7
Runowicz CD, Wadler S, Rodriguez-Rodriguez L, Litwin P, Shaves M, O'Hanlan KA et al. Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecologic Oncology. 1989;34(3):395-401. https://doi.org/10.1016/0090-8258(89)90180-7
Runowicz, Carolyn D. ; Wadler, Scott ; Rodriguez-Rodriguez, Lorna ; Litwin, Peter ; Shaves, Mark ; O'Hanlan, Katherine A. ; Goldberg, Gary L. ; Tomainov, Catherine T. ; Byrnes, Richard. / Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. In: Gynecologic Oncology. 1989 ; Vol. 34, No. 3. pp. 395-401.
@article{99a719ad8e4644ffa054b3fe4e00166f,
title = "Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma",
abstract = "Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.",
author = "Runowicz, {Carolyn D.} and Scott Wadler and Lorna Rodriguez-Rodriguez and Peter Litwin and Mark Shaves and O'Hanlan, {Katherine A.} and Goldberg, {Gary L.} and Tomainov, {Catherine T.} and Richard Byrnes",
year = "1989",
doi = "10.1016/0090-8258(89)90180-7",
language = "English (US)",
volume = "34",
pages = "395--401",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma

AU - Runowicz, Carolyn D.

AU - Wadler, Scott

AU - Rodriguez-Rodriguez, Lorna

AU - Litwin, Peter

AU - Shaves, Mark

AU - O'Hanlan, Katherine A.

AU - Goldberg, Gary L.

AU - Tomainov, Catherine T.

AU - Byrnes, Richard

PY - 1989

Y1 - 1989

N2 - Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.

AB - Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=1342314123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342314123&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(89)90180-7

DO - 10.1016/0090-8258(89)90180-7

M3 - Article

VL - 34

SP - 395

EP - 401

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -